In hepatocellular carcinoma, TFAP2A is a key player in the transcriptional regulation of a cluster of DNA damage repair genes: DNA repair is prevented by TFAP2A depletion, and the new TFAP2A inhibitor LEI110 shows anti-tumour efficacy in HCC cell lines. This evidence concerns the gene TFAP2A and neoplasm.